AVAILABLE MEDICINE FOR Osimertinib

Name	Price	Action
Osicent Osimertinib 80mg Tablets $120	$120
Osimert 80mg - Generic Tagrisso $130 $150	$130 $150
Tagrisso Osimertinib 80mg Tablets $1,668 - $4,288	$1,668 - $4,288
Tagrix Osimertinib 80mg Tablet $432 $598	$432 $598
Ositab 40mg Tablet		Ask for Price
Ositab 80mg Tablet $170 $200	$170 $200	Ask for Price

Showing 1 to 6 of 6 (1 Pages)

Introduction to Osimertinib

Osimertinib is classified as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is mainly designed to target mutations in the epidermal growth factor. Osimertinib is also known or marketed as Tagrisso. Osimertinib is widely used for treating non-small cell lung cancer (NSCLC) for patient with EGFR-mutated advanced or metastatic NSCLC for patient who have make headway after following initial epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment or possess the T790M mutation.

Osimertinib Mechanism of Action

Osimertinib functions by targeting and blocking mutation in epidermal growth factor receptors, including T790M, which often lead to resistance to first- and second-generation EGFR inhibitors. By inhibiting the signals or pathways that lead to the growth of cancer cells, it successfully and effectively prevents the growth and extension of non-small cell lung cancer (NSCLC). Osimertinib mechanism of action and clear-cut mode of action making it more effective and beneficial for lung cancer patients with EGFR mutations while reducing effects on normal and healthy cells.

Osimertinib FDA Approval and Indications

In November 2015, The FDA granted approval for Osimertinib for treating metastatic EGFR T790M mutation-positive NSCLC, especially after chemotherapy does not work. It is also used as a first-line treatment option for patients with advanced lung cancer. In 2020, the FDA expanded its label to be used after therapy to help prevent cancer from coming back in patients who have either EGFR 19 deletions or exon 21 L858R mutations.

Clinical Trials and Studies

The FLAURA and LAURA studies provided riveting evidence of improvement in progression-free survival (PFS) and overall survival (OS) for patients treated with Osimertinib, establishing it as a first-line treatment option. The LAURA trial unveiled drug effectiveness in the adjuvant context for patients with cross out EGFR-mutated NSCLC. Recent data findings from ASCO 2024 emphasized its important role to address resistance mechanisms.

Side Effects of Osimertinib

Some common Side effects of this drug may include:

Dry skin
Diarrhea
Nail toxicity
Rash
Fatigue
Decreased appetite

Some serious side effects involve:

Lung or heart disease
QT prolongation

Use in Chemotherapy and After Chemoradiotherapy

Osimertinib chemotherapy is different from conventional chemotherapy, as it is a targeted therapy. It specifically attacks cancer cells with certain mutations and is often used alone or in combination with chemotherapeutic agents for enhanced effectiveness. Clinical studies have looked at using Osimertinib after chemoradiotherapy in stage III non-small cell lung cancer (NSCLC) that has EGFR mutations. The research showed positive results in helping patients live longer without the cancer getting worse.

Conclusion

This drug represents a significant advancement in the treatment of non-small cell lung cancer NSCLC with epidermal growth factor receptor (EGFR) with its demonstrated effectiveness, improved survival rates or outcomes, and boosting accessibility, it remains an important option and choice for patients worldwide. For further details consult patient’s healthcare provider for more detailed and information about Osimertinib prescribing information